India's Bioeconomy to Reach $300 Bn by 2033 on Innovation Demand: Report Highlights

This, coupled with escalating drug development costs, now averaging around $2.2 billion per asset and development timelines stretching to nearly 100 months, creates a unique opportunity for India.

India’s biotech sector is on the cusp of a transformative phase, with its bioeconomy expected to soar from $10 billion in 2014 to approximately $195 billion by 2026, and nearly $300 billion by 2033, according to the report by Endiya Partners.

The report, “India’s Biopharma Moment: Perspectives from DEMO Biotech,” highlights a pivotal moment for India as a $300 billion global patent cliff approaches by 2030.

This, coupled with escalating drug development costs, now averaging around $2.2 billion per asset and development timelines stretching to nearly 100 months, creates a unique opportunity for India.

“India is transitioning from a global leader in generics to a high-velocity, cost-effective hub for biopharma innovation,” the report said, noting that the country already supplies around 20% of global generics and over 60% of vaccines.

The nation is emerging as a cost-effective solution, showcasing a “recruitment alpha” that allows for patient enrollment up to ten times faster and facilitates three to four times more drug development attempts for every dollar invested.

Support from the Indian government is significantly reinforcing this shift. Key initiatives like the ₹10,000 crore Biopharma Shakti scheme and the ₹1 lakh crore Research, Development, and Innovation (RDI) fund are strong indicators of policy evolution.

Additionally, the recent revisions to the New Drugs and Clinical Trials Rules in March 2026, which include a streamlined 45-day approval timeline and prior intimation pathways, are set to reduce development cycles by 90 to 120 days.

The expansion of India's biotech ecosystem is noteworthy, now comprising over 2,500 startups, around 100 incubators, over 600 research institutes, and 200 accredited laboratories.

This growth reflects a rising global recognition of Indian innovation, marked by significant cross-border partnerships, regulatory approvals, and advancements in clinical-stage developments.

Despite these advancements, challenges persist. Structural gaps such as limited pilot-scale good manufacturing practice (GMP) infrastructure, difficulties in securing late-stage funding, talent shortages, and inadequate translational research capabilities continue to hinder the scaling of innovation.

In light of these challenges, the report outlines four strategic priorities essential for maintaining momentum in India's biotech sector: developing blended financing models to mitigate risks in cutting-edge science, strengthening industrial intelligence, enhancing translational infrastructure, and fostering a more dynamic regulatory framework.

Stay tuned for more such updates on Digital Health News